Recent Quotes (30 days)

You have no recent quotes
chg | %

Stem Cell Therapeutics Corp  

(Public, CVE:SSS)   Watch this stock  
Find more results for SSS
0.345
+0.015 (4.55%)
Apr 16 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.34 - 0.35
52 week 0.14 - 0.74
Open 0.34
Vol / Avg. 103,450.00/249,977.00
Mkt cap 69.78M
P/E     -
Div/yield     -
EPS -0.08
Shares 202.27M
Beta 1.41
Inst. own     -
Feb 10, 2014
STEM CELL THERAPEUTICS CORP at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.69% -49.02%
Return on average equity -117.79% -55.99%
Employees 7 -
CDP Score - -

Address

96 Skyway Avenue
TORONTO, ON M9W 4Y9
Canada
+1-416-5950627 (Phone)

Website links

Description

Stem Cell Therapeutics Corp. (SCT) is a Canada-based biopharmaceutical company engaged in advancing cancer stem cell discoveries into cancer therapies. SCT�s clinical stage programs include the tigecycline program, which is being evaluated in a multi-centre Phase I study in patients with Acute Myeloid Leukemia (AML), as well as TTI-1612, a non-stem cell asset being tested in a 28-patient Phase I trial in interstitial cystitis (IC) patients. The Company also has two preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tum

Officers and directors

Calvin R. Stiller M.D. Independent Chairman of the Board
Age: 73
Niclas Stiernholm President, Chief Executive Officer, Director
James T. Parsons Chief Financial Officer
Bob Uger PhD Chief Scientific Officer
Penka Petrova Vice President - Drug Development
Scott Duncan Director - Intellectual Property
Luke M. Beshar CPA Director
Age: 54
Robert L. Kirkman M.D. Director
Age: 64
Thomas C. Reynolds M.D., Ph.D. Director
Age: 54
Henry Friesen M.D. Independent Director
Age: 78